AndrewDCampbellMD(He/Him)

Pediatric Hematology & Oncology • Washington, DC

Medical Director, Sickle Cell Program, Center for Cancer and Blood Disorders, Research Lead, Global Health Initiative Children's National Hospital Washington, DC Associate Professor of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC

Join to view full profile

Dr. Campbell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Campbell's full profile

Already have an account?

Office
111 Michigan Ave
Washington, DC 20010
Phone+1 888-884-2327

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Pediatric Hematology/Oncology, 1999 - 2002
Massachusetts General HospitalResidency, Pediatrics, 1996 - 1999
Case Western Reserve University School of MedicineClass of 1996

Certifications & Licensure

MD State Medical License 2017 - 2026
DC State Medical License 2017 - 2024
VA State Medical License 2020 - 2024
MI State Medical License 2002 - 2018
IL State Medical License 1999 - 2005
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Top Doctors Pediatric Hematology Oncology Castle Connolly Medical LTD, 2018-2023
Best Doctors in America, Pediatric Hematology/Oncology Best Doctors Inc., 2013-2018

Clinical Trials

Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease Start of enrollment: 2012 Mar 01
Completed
Phase 2
Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias Start of enrollment: 2014 Apr 17
Terminated
Phase 4
Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease Start of enrollment: 2016 Jul 05
Active, not recruiting
Phase 2
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) Start of enrollment: 2017 Dec 22
Completed
Phase 2
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients Start of enrollment: 2018 Oct 01
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

261 citations
Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.
Rene Jackstadt, Sander R. van Hooff, Joshua D.G. Leach, Xabier Cortes-Lavaud, Jeroen O. Lohuis
Cancer Cell. 2019-09-16
86 citations
Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease.
Mark C. Walters, Laura M. De Castro, Keith M. Sullivan, Lakshmanan Krishnamurti, Naynesh Kamani
Biology of Blood and Marrow Transplantation. 2016-02-01
41 citations
Mevalonate Pathway Provides Ubiquinone to Maintain Pyrimidine Synthesis and Survival in p53-Deficient Cancer Cells Exposed to Metabolic Stress
Irem Kaymak, Carina R. Maier, Werner Schmitz, Andrew D. Campbell, Beatrice Dankworth
Cancer Research. 2020-01-15

Journal Articles

Low nitric oxide level is implicated in sickle cell disease and its complications in Ghana
Antwi-Boasiako C, Campbell AD, Vascular Health and Risk Management, 9/6/2018

Abstracts/Posters

Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US
Andrew D. Campbell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

An Analysis of Racial and Ethnic Backgrounds within the Casire International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Re...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Outcomes in Children with Severe Vasculopathy from Sickle Cell Anemia after Treatment with Chronic Transfusion, Surgical Revascularization and/or Allogenic Hematopoeti...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Why Gene Therapy for Sickle Cell Is Slow to Catch on with PatientsSeptember 28th, 2024
Meet Dr. Andrew Campbell: Trailblazing Treatment for Patients with Sickle Cell DiseaseSeptember 24th, 2024
Dr. Andrew Campbell on Sickle Cell Advancements and Global Health InitiativesAugust 22nd, 2024
Join now to see all